This was announced by Alexey Alekhin, the Director of the Pharmaceutical and Medical Industry Development Department of the Russian Ministry of Industry and Trade, on the eve of the Russian Health Care Week, a forum.
“Next year, we are planning to achieve 90%,” said Mr. Alekhin.
According to the data for the first eight months of this year provided by the Ministry of Industry and Trade, the share of Russian-made drugs in the total market was 30.7%. For the first nine months of this year, the output of medicines in Russia grew by 11.7% compared to the same period of the last year and reached 213.2 billion rubles.
The exports of Russian-made drugs remained virtually at the level of the last year. In eight months of this year, the Russian pharmaceutical companies exported the products worth $400 million while, in 2016, the exports amounted to $540 million. The main importers are CIS countries, primarily, Kazakhstan, Ukraine, and Uzbekistan. The Ministry of Industry and Trade noted the growing interest to Russian-made medicinal products in Vietnam and Mongolia. According to Mr. Alekhin, the greatest demand abroad is the one for advanced Russian drugs for the treatment of cancer and rheumatoid arthritis.
The Russian government provides preferential loans and subsidies to the pharmaceutical companies in order to compensate for the costs of registration procedures when entering the foreign markets. In July, Prime Minister Dmitry Medvedev included the pharmaceuticals in the list of products for priority export support. The Ministry of Industry and Trade is also developing the additional tools.